Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/29906
Title: | Azithromycin during Acute Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization (BACE) A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial | Authors: | Vermeersch, Kristina Gabrovska, Maria AUMANN, Joseph Demedts, Ingel K. Corhay, Jean-Louis Marchand, Eric Slabbynck, Hans Haenebalcke, Christel Haerens, Michiel Hanon, Shane Jordens, Paul Peche, Rudi Fremault, Antoine Lauwerier, Tine Delporte, Anja Vandenberk, Bert Willems, Rik Everaerts, Stephanie Belmans, Ann BOGAERTS, Kris Verleden, Geert M. Troosters, Thierry Ninane, Vincent Brusselle, Guy G. Janssens, Wim Vincken, Walter Debrock, Alix Lamont, Jan Tits, Geert Delobbe, Alain Martinot, Jean-Benoit |
Issue Date: | 2019 | Publisher: | AMER THORACIC SOC | Source: | AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 200(7), p. 857-868 | Abstract: | Rationale: Azithromycin prevents acute exacerbations of chronic obstructive pulmonary disease (AECOPDs); however, its value in the treatment of an AECOPD requiring hospitalization remains to be defined. Objectives: We investigated whether a 3-month intervention with low-dose azithromycin could decrease treatment failure (TF) when initiated at hospital admission and added to standard care. Methods: In an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial, patients who had been hospitalized for an AECOPD and had a smoking history of pack >= 10 years and one or more exacerbations in the previous year were randomized (1:1) within 48 hours of hospital admission to azithromycin or placebo. The study drug (500 mg/d for 3 d) was administered on top of a standardized acute treatment of systemic corticosteroids and antibiotics, and subsequently continued for 3 months (250 mg/2 d). The patients were followed for 6 months thereafter. Time-to-first-event analyses evaluated the TF rate within 3 months as a novel primary endpoint in the intention-to-treat population, with TF defined as the composite of treatment intensification with systemic corticosteroids and/or antibiotics, a step-up in hospital care or readmission for respiratory reasons, or allcause mortality. Measurements and Main Results: A total of 301 patients were randomized to azithromycin (n = 147) or placebo (n = 154). The TF rate within 3 months was 49% in the azithromycin group and 60% in the placebo group (hazard ratio, 073; 95% confidence interval, 0.53-1.01; P = 0.0526). Treatment intensification, step-up in hospital care, and mortality rates within 3 months were 47% versus 60% (P = 0.0272), 13% versus 28% (P = 0.0024), and 2% versus 4% (P = 0.5075) in the azithromycin and placebo groups, respectively. Clinical benefits were lost 6 months after withdrawal. Conclusions: Three months of azithromycin for an infectious AECOPD requiring hospitalization may significantly reduce TF during the highest-risk period. Prolonged treatment seems to be necessary to maintain clinical benefits. | Notes: | [Vermeersch, Kristina; Everaerts, Stephanie; Verleden, Geert M.; Troosters, Thierry; Janssens, Wim] Katholieke Univ Leuven, Lab Resp Dis, Dept Chron Dis Metab & Ageing, Leuven, Belgium. [Belmans, Ann; Bogaerts, Kris] Katholieke Univ Leuven, I BioStat, Leuven, Belgium. [Troosters, Thierry] Katholieke Univ Leuven, Dept Rehabil Sci, Fac Kinesiol & Rehabil Sci, Leuven, Belgium. [Vermeersch, Kristina; Everaerts, Stephanie; Verleden, Geert M.; Janssens, Wim] Univ Hosp Leuven, Dept Resp Dis, Leuven, Belgium. [Vandenberk, Bert; Willems, Rik] Univ Hosp Leuven, Dept Cardiol, Leuven, Belgium. [Gabrovska, Maria; Ninane, Vincent] Univ Libre Bruxelles, Ctr Hosp Univ St Pierre, Dept Pneumol, Brussels, Belgium. [Aumann, Joseph] Jessa Ziekenhuis, Dept Pneumol, Hasselt, Belgium. [Demedts, Ingel K.] AZ Delta Roeselare Menen, Dept Resp Med, Roeselare, Belgium. [Corhay, Jean-Louis] Ctr Hosp Univ, Dept Pneumol, Liege, Belgium. [Marchand, Eric] CHU UCL Namur, Dept Pneumol, Yvoir, Belgium. [Marchand, Eric] Univ Namur, Lab Resp Physiol, Fac Med, NARILIS, Namur, Belgium. [Slabbynck, Hans] ZNA Middelhe, Dept Resp Med, Antwerp, Belgium. [Haenebalcke, Christel] Acad Hosp St Jan, Dept Pneumol, Brugge Oostende, Belgium. [Haerens, Michiel] AZ Groeninge, Dept Pneumol, Kortrijk, Belgium. [Hanon, Shane] UZ Brussel, Dept Pneumol, Jette, Belgium. [Jordens, Paul] Onze Lieve Vrouw Hosp, Dept Pneumol, Aalst, Belgium. [Peche, Rudi] Ctr Hosp Univ Charleroi, Dept Pneumol, Charleroi, Belgium. [Fremault, Antoine] Grand Hop Charleroi, Dept Pneumol, Charleroi, Belgium. [Lauwerier, Tine] Imelda Ziekenhuis, Dept Pneumol, Bonheiden, Belgium. [Delporte, Anja; Brusselle, Guy G.] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium. [Belmans, Ann; Bogaerts, Kris] Univ Hasselt, Hasselt, Belgium. [Ninane, Vincent] CHU St Pierre, Brussels, Belgium. [Aumann, Joseph] Jessa Ziekenhuis, Hasselt, Belgium. [Demedts, Ingel K.] AZ Delta, Roeselare Menen, Belgium. [Slabbynck, Hans] ZNA Middelheim, Antwerp, Belgium. [Marchand, Eric] CHU UCL Namur, Yvoir, Belgium. [Haenebalcke, Christel] AZ St Jan Ziekenhuis, Brugge, Belgium. [Peche, Rudi] CHU Charleroi, Charleroi, Belgium. [Brusselle, Guy G.] UZ Gent, Ghent, Belgium. [Vincken, Walter] UZ Brussel, Brussels, Belgium. [Corhay, Jean-Louis] CHU Liege, Luik, Belgium. [Haerens, Michiel] AZ Groeninge, Kortrijk, Belgium. [Fremault, Antoine] Grand Hop Charleroi, Charleroi, Belgium. [Lauwerier, Tine] Imelda Ziekenhuis, Bonheiden, Belgium. [Debrock, Alix] St Augustinus Ziekenhuis, Antwerp, Belgium. [Lamont, Jan] Maria Middelares Ziekenhuis, Ghent, Belgium. [Tits, Geert] St Andriesziekenhuis, Tielt, Belgium. [Jordens, Paul] Onze Lieve Vrouw Hosp, Aalst, Belgium. [Delobbe, Alain] Clin Reine Astrid, Malmedy, Belgium. [Martinot, Jean-Benoit] Clin Ste Elisabeth, Namur, Belgium. | Keywords: | macrolide; composite; time to event; treatment failure; readmission;macrolide; composite; time to event; treatment failure; readmission | Document URI: | http://hdl.handle.net/1942/29906 | ISSN: | 1073-449X | e-ISSN: | 1535-4970 | DOI: | 10.1164/rccm.201901-0094OC | ISI #: | 000488777100015 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2020 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
vermeersch2019.pdf Restricted Access | Published version | 1.81 MB | Adobe PDF | View/Open Request a copy |
Ordner1.pdf | Peer-reviewed author version | 2.14 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.